The dawn of personalized DNA vaccines: Asked & answered feature

In a groundbreaking Q&A with Inside Precision Medicine, Dr. Luigi Aurisicchio, CEO of Neomatrix Biotech, shares how his company is redefining the future of personalized cancer treatment through synthetic DNA-based neoantigen vaccines. By combining advanced tumor profiling with enzymatically produced DNA and rapid manufacturing timelines, Neomatrix is pioneering a new generation of cancer vaccines that can be delivered within just six weeks of biopsy, a crucial advantage in the fight against aggressive tumors.

In the interview, Aurisicchio highlights why Neomatrix chose synthetic DNA over traditional plasmid or mRNA platforms, citing speed, safety, and scalability as core benefits. With support from 4basebio’s synthetic DNA technology, Neomatrix is preparing for its first clinical trial in lung cancer and developing strategies to adapt vaccines in real time using circulating tumor DNA. Read the full conversation to explore how this innovative approach could transform cancer immunotherapy and deliver truly individualized treatments.